Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 70,384 shares of Tevogen Bio stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $1.09, for a total value of $76,718.56. Following the completion of the transaction, the insider now owns 3,898,828 shares of the company's stock, valued at approximately $4,249,722.52. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Neal Flomenberg also recently made the following trade(s):
Shares of NASDAQ TVGN traded up $0.01 during midday trading on Tuesday, hitting $1.07. 363,430 shares of the company's stock were exchanged, compared to its average volume of 5,078,983. Tevogen Bio Holdings Inc. has a twelve month low of $0.26 and a twelve month high of $6.95. The stock's 50 day moving average price is $1.36 and its 200-day moving average price is $1.17.
Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Tevogen Bio in a report on Tuesday.
Check Out Our Latest Research Report on TVGN
A number of institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tevogen Bio during the fourth quarter valued at $38,000. JPMorgan Chase & Co. grew its position in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares in the last quarter. Barclays PLC grew its position in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new position in Tevogen Bio during the 4th quarter valued at about $55,000. Finally, HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio during the 3rd quarter worth about $82,000.
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.